Global Non-Small Cell Lung Cancer Epidemiology Insights

Thelansis’s “Global Non-Small Cell Lung Cancer Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Non-Small Cell Lung Cancer Overview

Non‑small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 85% of all cases. Around 15–20% are diagnosed at an early stage, where surgical resection, often combined with adjuvant chemotherapy or radiotherapy, offers the best chance of cure. Risk factors can be divided into modifiable and non‑modifiable categories. Modifiable risks include tobacco smoking, secondhand smoke, and occupational or environmental exposures such as asbestos, radon, arsenic, chromium, nickel, ionizing radiation, and polycyclic aromatic hydrocarbons. Non‑modifiable risks include age, family history, and genetic predisposition. Additionally, prior chest irradiation for malignancies such as breast cancer or Hodgkin lymphoma increases the likelihood of developing NSCLC later in life.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)